Mingjing He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mingjing He has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Yong Wan
Department of Pharmacology and Chemical Biology Emory University School of Medicine Atlanta GA 30322 USA
4 shared publications - Zhuan Zhou
Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
4 shared publications - Anil A. Shah
Division of Vascular Surgery, Department of Thoracic and Cardiovascular surgery, Allegheny Health Network, Pittsburgh, PA, USA
3 shared publications - Qianming Chen
Stomatology Hospital, School of Stomatology, Zhejiang University School of Medicine, Hangzhou, China
3 shared publications - George Wu
Department of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
1 shared publication - Haojing Zou
Department of Cell Biology, University of Pittsburgh School of Medicine, 5117 Centre Avenue, Hillman Cancer Center, HCC2.6c, Pittsburgh, PA 15213 USA
1 shared publication
Latest Publications
- 1 September 2017
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 177, 96-107
Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication
- 1 September 2017
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 177, 96-107
Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication
- Open Access
- 20 December 2016
- Published by Springer Nature in Cell & Bioscience
- Vol. 6 (1) , 1-15
The emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics
The addition of mono-ubiquitin or poly-ubiquitin chain to signaling proteins in response to DNA damage signal is thought to be a critical event that facilitates the recognition of DNA damage lesion site, the activation of checkpoint function, termination and checkpoint response and the recruitment of DNA repair proteins. Despite the ubiquitin modifiers, removal of ubiquitin from the functional proteins by the deubiquitinating enzymes (DUBs) plays an important role in orchestrating DNA damage response as well as DNA repair processes. Deregulated ubiquitination and deubiquitination could lead to genome instability that in turn causes tumorigenesis. Recent TCGA study has further revealed the connection between mutations in alteration of DUBs and various types of tumors. In addition, emerging drug design based on DUBs provides a new avenue for anti-cancer therapy. In this review, we will summarize the role of deubiquitination and specificity of DUBs, and highlight the recent discoveries of DUBs in the modulation of ubiquitin-mediated DNA damage response and DNA damage repair. We will furthermore discuss the DUBs involved in the tumorigenesis as well as interception of deubiquitination as a novel strategy for anti-cancer therapy.
- 20 December 2016
- Published by Springer Nature in Cell & Bioscience
- Vol. 6 (1) , 1-15
Open AccessThe emerging role of deubiquitinating enzymes in genomic integrity, diseases, and therapeutics
The addition of mono-ubiquitin or poly-ubiquitin chain to signaling proteins in response to DNA damage signal is thought to be a critical event that facilitates the recognition of DNA damage lesion site, the activation of checkpoint function, termination and checkpoint response and the recruitment of DNA repair proteins. Despite the ubiquitin modifiers, removal of ubiquitin from the functional proteins by the deubiquitinating enzymes (DUBs) plays an important role in orchestrating DNA damage response as well as DNA repair processes. Deregulated ubiquitination and deubiquitination could lead to genome instability that in turn causes tumorigenesis. Recent TCGA study has further revealed the connection between mutations in alteration of DUBs and various types of tumors. In addition, emerging drug design based on DUBs provides a new avenue for anti-cancer therapy. In this review, we will summarize the role of deubiquitination and specificity of DUBs, and highlight the recent discoveries of DUBs in the modulation of ubiquitin-mediated DNA damage response and DNA damage repair. We will furthermore discuss the DUBs involved in the tumorigenesis as well as interception of deubiquitination as a novel strategy for anti-cancer therapy.
- Open Access
- 31 March 2016
- Published by Springer Nature in Cell Division
- Vol. 11 (1) , 1-10
New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics
PTMs (posttranslational modifications) such as ubiquitylation, sumoylation, acetylation and protein methylation are pivotal modifiers that determine the activation, deactivation or subcellular localization of signaling proteins, facilitating the initiation, amplification and transduction of signaling. Accumulating evidence suggest that several key signaling molecules in Hippo signaling pathway are tightly regulated by various types of PTMs. Malfunction of these critical signaling modules such as YAP/TAZ, MAT1/2 and LATS1/2 due to deregulated PTMs has been linked to a variety of human diseases such as cancer. In this review article, we summarized the current understanding of the impact of PTMs in regulating Hippo signaling pathway and further discussed the potential therapeutic intervention from the view of PTMs and Hippo pathway.
- 31 March 2016
- Published by Springer Nature in Cell Division
- Vol. 11 (1) , 1-10
Open AccessNew insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics
PTMs (posttranslational modifications) such as ubiquitylation, sumoylation, acetylation and protein methylation are pivotal modifiers that determine the activation, deactivation or subcellular localization of signaling proteins, facilitating the initiation, amplification and transduction of signaling. Accumulating evidence suggest that several key signaling molecules in Hippo signaling pathway are tightly regulated by various types of PTMs. Malfunction of these critical signaling modules such as YAP/TAZ, MAT1/2 and LATS1/2 due to deregulated PTMs has been linked to a variety of human diseases such as cancer. In this review article, we summarized the current understanding of the impact of PTMs in regulating Hippo signaling pathway and further discussed the potential therapeutic intervention from the view of PTMs and Hippo pathway.
- Open Access
- 1 March 2016
- Published by Springer Nature in Cell Division
- Vol. 11 (1) , 1-18
Insights into APC/C: from cellular function to diseases and therapeutics
Anaphase-promoting complex/cyclosome (APC/C) is a multifunctional ubiquitin-protein ligase that targets different substrates for ubiquitylation and therefore regulates a variety of cellular processes such as cell division, differentiation, genome stability, energy metabolism, cell death, autophagy as well as carcinogenesis. Activity of APC/C is principally governed by two WD-40 domain proteins, Cdc20 and Cdh1, in and beyond cell cycle. In the past decade, the results based on numerous biochemical, 3D structural, mouse genetic and small molecule inhibitor studies have largely attracted our attention into the emerging role of APC/C and its regulation in biological function, human diseases and potential therapeutics. This review will aim to summarize some recently reported insights into APC/C in regulating cellular function, connection of its dysfunction with human diseases and its implication of therapeutics.
- 1 March 2016
- Published by Springer Nature in Cell Division
- Vol. 11 (1) , 1-18
Open AccessInsights into APC/C: from cellular function to diseases and therapeutics
Anaphase-promoting complex/cyclosome (APC/C) is a multifunctional ubiquitin-protein ligase that targets different substrates for ubiquitylation and therefore regulates a variety of cellular processes such as cell division, differentiation, genome stability, energy metabolism, cell death, autophagy as well as carcinogenesis. Activity of APC/C is principally governed by two WD-40 domain proteins, Cdc20 and Cdh1, in and beyond cell cycle. In the past decade, the results based on numerous biochemical, 3D structural, mouse genetic and small molecule inhibitor studies have largely attracted our attention into the emerging role of APC/C and its regulation in biological function, human diseases and potential therapeutics. This review will aim to summarize some recently reported insights into APC/C in regulating cellular function, connection of its dysfunction with human diseases and its implication of therapeutics.